Pfizer · NSE: PFIZER · BSE: 500680
Q3 FY22 results · Oct–Dec 2021
Pfizer reported revenue from operations of ₹675.90 crore (up 13.9% from Q3 FY21) and net profit of ₹143.91 crore (up 1.9% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 675.90 | 593.49 | +13.9% | 636.26 | +6.2% |
| Other income | 18.26 | 14.57 | +25.3% | 15.03 | +21.5% |
| Total income | 694.16 | 608.06 | +14.2% | 651.29 | +6.6% |
| Profit before tax | 184.09 | 180.26 | +2.1% | 174.96 | +5.2% |
| Net profit for the period | 143.91 | 141.24 | +1.9% | 142.95 | +0.7% |
| EPS, basic (₹) | 31.46 | 30.87 | +1.9% | 31.25 | +0.7% |
| Net margin (%) | 21.3 | 23.8 | 22.5 |
Standalone
- Filed with BSE
- 03 Feb 2022, 17:03 IST
- Board meeting
- 03 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE